Drugs.com - Pharma News

Hospira challenges patents on Cubist antibiotic

Thu, 09 Feb 2012 21:45:38 GMT

From Associated Press (February 9, 2012) LEXINGTON, Mass. -- Cubist Pharmaceuticals Inc. said Thursday that Hospira Inc. is challenging the patents supporting its antibiotic Cubicin, which brings in almost all of Cubist's revenue. Cubist said it...

2011 Health Spending Growth Remains Near Historic Lows

Thu, 09 Feb 2012 17:26:27 GMT

ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb 9, 2012 - New analysis shows that health care spending in the U.S. in 2011 grew at one of the slowest rates in 50 years according to the February Health Sector Economic Indicators briefs released today by...

SEC Charges Former Pharmaceutical Company Employee with Insider Trading on Biotech Deals

Thu, 09 Feb 2012 16:51:44 GMT

WASHINGTON, Feb. 9, 2012 — The Securities and Exchange Commission today charged that a former employee of Takeda Pharmaceuticals International, Inc. traded on inside information about the Japanese firm’s business alliances and...

India's Global Pharmacy Role Threatened By EU Pact

Thu, 09 Feb 2012 14:49:25 GMT

From Associated Press (February 9, 2012) NEW DELHI -- Efforts by India and the European Union to strengthen trade are threatening India's ability to deliver life-saving medicines to the world's poorest, analysts say as the two sides resume...

Leo Pharma Sales Reps File Overtime Class Action in New York Federal Court

Thu, 09 Feb 2012 14:25:36 GMT

Complaint Filed by Sanford Wittels & Heisler, LLP Details Current and Past Federal & State Wage and Hour Violations NEW YORK, Feb. 9, 2012 /PRNewswire/ -- Just weeks after winning preliminary approval of a 99 million dollar settlement on...

Bayer and Almirall to Co-Promote Anticoagulant Rivaroxaban in Spain

Thu, 09 Feb 2012 13:59:12 GMT

Bayer and Almirall to co-promote anticoagulant Rivaroxaban in Spain •Rivaroxaban an innovative oral anticoagulant developed by Bayer, is a new option for stroke prevention in atrial fibrillation recently approved in Europe and the United...

Ernst-&-Young-Fined

Thu, 09 Feb 2012 13:29:10 GMT

US-Ernst-&-Young-Fined From Canadian Press Broadcast Wire (Canada) (February 8, 2012) WASHINGTON - The watchdog agency for the accounting industry said Wednesday that it has fined big firm Ernst & Young $2 million for alleged lapses in three...

'Rx' Is Stylish, Clever Satire of Drug Companies

Thu, 09 Feb 2012 13:29:07 GMT

From Associated Press (February 8, 2012) NEW YORK -- A lot of people hate their jobs, but not to worry: there could soon be a pill for that. In the greedy world of pharmaceutical marketing as darkly imagined by playwright Kate Fodor, workplace...

Alexion Acquires Enobia Pharma For $1.1 Billion

Thu, 09 Feb 2012 13:28:43 GMT

Alexion Acquires Enobia Pharma For $1.1 Billion [The Hartford Courant, Conn.] From Hartford Courant (CT) (February 8, 2012) Feb. 08--Alexion Pharmaceuticals Inc., a Cheshire biopharmaceutical company that develops treatments for rare disorders, has...

Aldagen Sold for More Than $40M

Thu, 09 Feb 2012 13:19:45 GMT

Aldagen sold to Md. company for more than $40M [The News & Observer, Raleigh, N.C.] From News & Observer (Raleigh, NC) (February 9, 2012) Feb. 09--Aldagen, a Durham biotechnology company whose attempts to go public didn't pan out, has been...

Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34

Thu, 09 Feb 2012 13:03:05 GMT

Good 2012 earnings growth expected DUBLIN, Ireland, February 9, 2012 /PRNewswire/ --Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the year to December 31, 2011. Financial Highlights ...

Impax Laboratories Provides Update on Status of Warning Letter Resolution for its Hayward Facility

Thu, 09 Feb 2012 12:30:04 GMT

Outlines Progress in Executing Growth Strategy and on Implementing Quality Improvement Initiatives HAYWARD, Calif.--(BUSINESS WIRE)--Feb 9, 2012 - Impax Laboratories, Inc. (NASDAQ: IPXL) today provided an update on the status of its resolution of...

Proton Pump Inhibitors (PPIs) - Drug Safety Communication: Clostridum Difficile-Associated Diarrhea (CDAD) Can be Associated With Stomach Acid Drugs

Wed, 08 Feb 2012 16:15:56 GMT

AcipHex (rabeprazole sodium) Dexilant (dexlansoprazole) Nexium (esomeprazole magnesium)? Omeprazole (omeprazole) Over-the-Counter (OTC) Prevacid (lansoprazole) and OTC Prevacid 24hr Prilosec (omeprazole)? and OTC...

GSK Adjusting Its R&D Efforts

Wed, 08 Feb 2012 15:14:17 GMT

GSK adjusting its R&D efforts [The News & Observer, Raleigh, N.C.] From News & Observer (Raleigh, NC) (February 8, 2012) Feb. 08--GlaxoSmithKline's plans for reconfiguring its research-and-development efforts aim to...

College Vending Machine Dispenses 'Morning-After' Pill

Wed, 08 Feb 2012 14:02:11 GMT

Pa. vending machine dispenses 'morning-after' pill From Associated Press (February 8, 2012) Students at Shippensburg University in Pennsylvania can get the "morning-after" pill by sliding $25 into a vending machine, an idea that has drawn...

Sanofi: 2011 Results Benefit from Genzyme Acquisition

Wed, 08 Feb 2012 12:35:11 GMT

Net Sales and Business EPS(1) up 9.2%(2) in Q4 PARIS, February 08, 2012, 2012 /PRNewswire/ -- (Logo : http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Change at ...

Roche disappointed by the actions of Illumina, Inc.'s Board of Directors

Wed, 08 Feb 2012 12:31:01 GMT

Roche's offer provides full and fair value for Illumina shareholders BASEL, Switzerland--(BUSINESS WIRE)--Feb 8, 2012 - Roche (SIX: RO, ROG; OTCQX: RHHBY) released the following statement in response to the announcement by Illumina, Inc. (NASDAQ:...

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

Wed, 08 Feb 2012 12:29:42 GMT

PARIS & NEW YORK--(BUSINESS WIRE)--Feb 8, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to...

FDA Will Speed Up Review of Roche Cancer Drug

Wed, 08 Feb 2012 12:02:22 GMT

From Associated Press (February 7, 2012) NEW YORK -- Swiss drugmaker Roche said Tuesday that the Food and Drug Administration will make a decision on its experimental breast cancer drug pertuzumab by June. Roche's Genentech business aid the...

Sanofi Wins US Approval for Anti-Lice Shampoo

Wed, 08 Feb 2012 12:02:06 GMT

From Associated Press (February 7, 2012) WASHINGTON -- Drugmaker Sanofi said Tuesday it received U.S. approval for a prescription-strength shampoo to treat head lice in children six months old and up. The company's Sklice Lotion uses a...

Illumina's Board Unanimously Rejects Roche's Unsolicited Tender Offer as Inadequate

Tue, 07 Feb 2012 21:34:23 GMT

Urges Stockholders Not to Tender Their Shares Files 14D-9 with SEC Detailing Reasons for Board's Recommendation Hosts Conference Call for Investors at 5:00 PM ET SAN DIEGO--(BUSINESS WIRE)--Feb 7, 2012 - Illumina, Inc. (NASDAQ:ILMN), a leading...

GSK Upbeat on Solid Results - Interviews with CEO and CFO

Tue, 07 Feb 2012 16:25:50 GMT

LONDON, February 7, 2012/PRNewswire-FirstCall/ -- In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned...

Edarbyclor (azilsartan medoxomil and chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension

Tue, 07 Feb 2012 14:02:31 GMT

DEERFIELD, Ill., February 6, 2012 and Osaka, Japan, February 7, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced EDARBYCLOR (azilsartan medoxomil and...

GlaxoSmithKline Shares Edge Lower As Fourth Quarter Figures Prove Slight Disappointment

Tue, 07 Feb 2012 13:16:51 GMT

Guardian Web (February 7, 2012) GlaxoSmithKline's results are out and they seem to have slightly disappointed the market. The pharmaceuticals group said fourth quarter turnover was down 3% at £6.98bn with earnings per share...

Amylin Takes 4Q Loss As Lilly Partnership Ends

Tue, 07 Feb 2012 13:11:20 GMT

From Associated Press (February 7, 2012) SAN DIEGO -- Diabetes drug maker Amylin Pharmaceuticals Inc. reported a larger fourth-quarter loss Monday after it ended a partnership with Eli Lilly & Co., which gave Amylin all the...

Drug That Prevents Breast Cancer in Some Women Hard on Bones: Study

Tue, 07 Feb 2012 13:02:37 GMT

From Canadian Press DataFile (February 6, 2012) By Sheryl Ubelacker TORONTO _ A drug shown to be highly effective in preventing breast cancer in postmenopausal women at high risk for the disease appears to worsen age-related bone loss, despite...

Cipher achieves sales milestone for Lipofen

Mon, 06 Feb 2012 17:37:21 GMT

www.cipherpharma.com. carmitage@equicomgroup.com Larry Andrews President and CEO Cipher Pharmaceuticals (905) 602-5840 ext 324 (905) 602-0628 faxlandrews@cipherpharma.com Craig Armitage Investor...

Cegedim Strategic Data (CSD) Tracks Pharmaceutical Companies' Print Advertising Investments

Mon, 06 Feb 2012 14:06:53 GMT

Rate of Decline in Print Advertising Investments Slows to 4% for 12 Months Ending September 2011 Across Ten Key Markets PARIS--(Marketwire - Feb 6, 2012) - Cegedim Strategic Data (CSD) (www.cegedimstrategicdata.com), leading provider of...

Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia

Mon, 06 Feb 2012 13:58:00 GMT

Company Confirms Plans to File NDA for Suvorexant in 2012 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 6, 2012 - Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for...

Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK ?052 Phase 1 and 2 Clinical Trials

Mon, 06 Feb 2012 13:57:39 GMT

PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 6, 2012 - Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its partner GlaxoSmithKline (GSK) has voluntarily paused enrollment in its current clinical trials of GSK2251052 (GSK ˜052) due to...

Astellas Pharma Inc.: Reorganization of Astellas?Global Management Structure

Mon, 06 Feb 2012 13:41:22 GMT

February 6, 2012 Astellas Pharma Inc.: Reorganization of Astellas’Global Management Structure Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it will implement revisions...

Five Years After HPV Vaccine Law, Virginia Remains Split

Mon, 06 Feb 2012 13:02:59 GMT

Five Years After HPV Vaccine Law, State Remains Split [Virginian - Pilot] From Virginian - Pilot (February 5, 2012) By Elizabeth Simpson | The Virginian-Pilot Tonya McKinney was so intent on her daughter receiving the human papillomavirus...

Pharma cos need to compensate clinical trial victims, rules govt

Mon, 06 Feb 2012 12:59:48 GMT

Pharma cos need to compensate clinical trial victims, rules govt [Financial Express (India)] From Financial Express (India) (February 3, 2012) The government has made it mandatory for pharmaceutical companies sponsoring clinical trials in the...

Cardinal Health Statement Regarding Temporary Restraining Order to Avoid Disruption in Controlled Medicine Shipments From Florida

Mon, 06 Feb 2012 12:10:41 GMT

DUBLIN, Ohio, Feb. 3, 2012 /PRNewswire/ -- Today Cardinal Health was granted a temporary restraining order against the Drug Enforcement Administration's (DEA) immediate suspension order of its Lakeland, Fla. DEA...

Cardinal Health Inc. Seeks Restraining Order to Avoid Disruption in Controlled Medicine Shipments from Florida

Fri, 03 Feb 2012 17:16:14 GMT

DUBLIN, Ohio, Feb. 3, 2012 /PRNewswire/ -- Cardinal Health, one of the nation's largest health care distributors, today said it will vigorously contest the Drug Enforcement Administration's (DEA) immediate suspension of its license to distribute...

Montreal Pharma Research Cluster Threatened Again As AstraZeneca Closes Lab

Fri, 03 Feb 2012 15:11:04 GMT

From Canadian Press DataFile (February 2, 2012) By Ross Marowits MONTREAL -- Montreal’s status as a pharmaceutical research centre is under further threat as global giants adjust to the loss of patent protection for blockbuster drugs and...

Federal Court Dismisses Whistleblower Lawsuit Against Millennium Laboratories

Fri, 03 Feb 2012 13:52:01 GMT

Millennium Leads Industry Initiative and Calls on Other Laboratories to Implement Higher Compliance Standards; Funds a National Summit Chaired by Dr. Richard Payne, Professor of Medicine and Divinity at Duke University for Establishment of Industry...

Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184

Fri, 03 Feb 2012 13:12:21 GMT

CAMBRIDGE, Mass., Feb. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received...

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.

Fri, 03 Feb 2012 12:41:34 GMT

NEW YORK--(BUSINESS WIRE)--Feb 3, 2012 - Bristol-Myers Squibb Company (NYSE: BMY) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR) for its tender offer for Inhibitex, Inc....

Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results

Fri, 03 Feb 2012 12:25:39 GMT

- Fourth Quarter Product Sales of $2.13 Billion, up 11% Year over Year - - Full Year 2011 Product Sales of $8.10 Billion, up 10% over 2010 - - Full Year 2011 Non-GAAP EPS of $3.86, up 5% over 2010 - - Full Year 2011 Operating Cash Flows of $3.64...